Natalie I. Vokes

1 month ago | patientpower.info | Lindsay Modglin |Natalie I. Vokes

Jump ToWhat It IsWhy It's ImportantHow It's DoneWhen It's PerformedEGFR MutationsBenefitsConsiderationsTakeawayA mutation is a change in the DNA sequence of a gene, which can result in abnormal protein production. While not all DNA mutations are harmful, some mutations signal the development and progression of diseases such as cancer. These same mutations give your doctor important information about how your cancer may respond to different treatments.

1 month ago | patientpower.info | Lindsay Modglin |Natalie I. Vokes

Jump ToNSCLC BasicsSurvival RatesFactors Affecting Survival RatesAdvances in TreatmentTips to Improve SurvivalTakeawayNon-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It typically grows and spreads slower than small cell lung cancer (SCLC). Unlike SCLC, where the cancer cells look small and round, NSCLC cells are larger and more irregular in shape. Most people don't experience symptoms until the disease reaches advanced stages.

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.